Osage University Partners has contributed to a series A round for Vor Biopharma, an oncology drug developer based on work by Siddhartha Mukherjee at Columbia University.
Vor Biopharma, a US-based cancer treatment developer based on research at Columbia University, closed a $42m series A round on Thursday that included spinout-focused investment firm Osage University Partners. Venture capital firm 5AM Ventures and investment firm RA Capital Management co-led the round, which also featured pharmaceutical companies PureTech Health and Novartis, as well as medical…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
